Modulating effects of indoles on benzo[a]pyrene-induced sister chromatid exchanges and the balance between
W M Jongen1, R J Topp, P J van Bladeren
1Department of Toxicology, Agricultural University, De Dreyen 12, 6703 BC Wageningen, The Netherlands.
Abstract:
The modulating effects of indole-3-carbinol (I3C) and indole-3-acetonitrile (I3A) on sister chromatid exchange (SCE) induction by benzo[a]pyrene (B[a]P) was studied. Pretreatment of cultured primary chick-embryo hepatocytes with I3C and I3A resulted in a decrease in the number of B[a]P-induced SCEs for both compounds in co-cultured V79 Chinese hamster cells. At 25 μg/ml I3C caused a twofold increase in UDP-glucuronyltransferase (UDPGT) activity. No induction of glutathione-S-transferase was found. When I3A was used (35 μg/ml), UDPGT was increased twofold whereas again no increase in glutathione-S-transferase activity was observed. When induction ratios between UDPGT activity and cytochrome P-450 content were studied, induction with both I3C and I3A resulted in ratios (UDPGT activity/cytochrome P-450 content) comparable with the control situation, whereas induction with 3-methylcholanthrene (3-MC) resulted in a considerable decrease in this ratio. Pretreatment with I3C resulted in a considerable increase in the total conversion of B[a]P into water-soluble metabolites. When the relative amounts of the individual metabolites were compared with those obtained after 3-MC pretreatment no significant differences could be observed. The results indicate that modulating effects of indoles are not directly related to induction of cytochrome P-450-associated enzymes.
More Related Videos
09:19Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
05:27Gap Junctional Intercellular Communication: A Functional Biomarker to Assess Adverse Effects of Toxicants and Toxins, and Health Benefits of Natural Products
Published on: December 25, 2016
Related Concept Videos
Mutagenicity and Carcinogenicity
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
The drug's acidity or basicity is essential in determining the metabolic...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
